Medexus Pharmaceuticals Inc. (TSE:MDP - Free Report) - Research analysts at Raymond James cut their Q4 2026 earnings estimates for shares of Medexus Pharmaceuticals in a note issued to investors on Thursday, February 6th. Raymond James analyst M. Freeman now anticipates that the company will earn $0.06 per share for the quarter, down from their prior estimate of $0.07. Raymond James currently has a "Strong-Buy" rating and a $4.00 target price on the stock. The consensus estimate for Medexus Pharmaceuticals' current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals' FY2028 earnings at $2.16 EPS and FY2029 earnings at $3.07 EPS.
Other analysts have also recently issued reports about the stock. Ventum Cap Mkts upgraded shares of Medexus Pharmaceuticals to a "strong-buy" rating in a report on Friday, January 17th. Leede Financial raised shares of Medexus Pharmaceuticals from a "moderate buy" rating to a "strong-buy" rating in a research note on Wednesday, January 22nd. Ventum Financial raised their price objective on shares of Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the stock a "buy" rating in a research note on Thursday, January 30th. Stifel Nicolaus lowered shares of Medexus Pharmaceuticals from a "buy" rating to a "hold" rating and decreased their price objective for the stock from C$6.00 to C$3.45 in a research note on Friday, February 7th. Finally, Stifel Canada lowered shares of Medexus Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of C$5.49.
View Our Latest Research Report on Medexus Pharmaceuticals
Medexus Pharmaceuticals Stock Up 0.6 %
TSE:MDP traded up C$0.02 during trading hours on Monday, reaching C$3.14. 32,472 shares of the company's stock were exchanged, compared to its average volume of 184,147. The company has a market capitalization of C$70.30 million, a P/E ratio of 15.02 and a beta of 1.96. Medexus Pharmaceuticals has a 12 month low of C$1.47 and a 12 month high of C$5.56. The business's 50-day simple moving average is C$3.56 and its two-hundred day simple moving average is C$2.85.
About Medexus Pharmaceuticals
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
See Also
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
